MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.10) by 20 percent. This is a 33.33 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $8.51 million which missed the analyst consensus estimate of $9.57 million by 11.15 percent. This is a 18.43 percent decrease over sales of $10.43 million the same period last year.